July 20, 2024
Investors

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioVie Inc. Investors with Losses to Inquire About Securities Class Action Investigation – BIVI -December 22, 2023 at 07:50 pm EST


Official BIOVIE INC. press release

New York, New York–(Newsfile Corp. – December 22, 2023) – WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BioVie Inc. (NASDAQ: BIVI) resulting from allegations that BioVie may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased BioVie securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On September 26, 2023, BioVie announced completion of the last treatment visit in its Phase 3 clinical trial of NE3107. On November 8, 2023, BioVie revealed that “during routine monitoring of blinded data from our Phase 3 study of…NE3107, we uncovered what appears to be potential scientific misconduct and significant non-compliance with [Good Clinical Practice] (“GCPs”) and regulations at six sites[]” and “[w]e have alerted the [Federal Drug Administration’s] (“FDA’s”) Office of Scientific Integrity (‘OSI’) about these issues[.]”

On this news, BioVie’s stock price fell $1.25 per share, or 29.34%, to close at $3.01 per share on November 9, 2023.

Then, on November 29, 2023, BioVie announced that the Phase 3 trial missed statistical significance “due to site exclusions” and blamed the miss on “significant deviation from protocol and [GCP] violations at 15 sites” leading it to exclude all patients from these sites and referrals of them to the OSI.

On this news, BioVie’s stock price fell $3.03 per share, or 60.72%, to close at $1.96 per share on November 29, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/192228





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline